Targeted Resequencing of Epilepsy Genes: A Pharmaco-Therapeutic PerspectiveAnna Moles1,2*, Pantaleo Romanelli3, Federico Zara4, Pasquale Striano4, Saskia Biskup5 and Roberto Coccurello2
- *Corresponding Author:
- Anna Moles
Head of Laboratory, Italian National Research Council (C.N.R.)
Institute of Cell Biology and Neurobiology (IBCN), Rome, Italy
E-mail: [email protected]
Received date: July 18, 2014; Accepted date: August 30, 2014; Published date: September 08, 2014
Citation: Moles A, Romanelli P, Zara F, Striano P, Biskup S, et al. (2014) Targeted Resequencing of Epilepsy Genes: A Pharmaco-Therapeutic Perspective. Int J Neurorehabilitation 1:116. doi:10.4172/2376-0281.1000116
Copyright: © 2014 Moles A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
More than half of all epilepsies have some genetic basis and single gene defects in ion channels or neurotransmitter receptors are associated with some inherited forms of epilepsy. Genetic research even in the field of epilepsy disorders is increasing in term of testing platform for the investigation of sequence and structural variation. Next generation sequencing (NGS), i.e., high-throughput sequencing technologies now allow analyses that were previously prohibitive. Targeted resequencing methods by diagnostic panels enable to sequence all the genes associated with a certain disease simultaneously within a few weeks. In this review, we will discuss the overall helpfulness and convenience of simultaneous genotyping of multiple epilepsy genes by NGS in a pharmacogenetics perspective.